摘要
目的探讨银杏达莫联合奥拉西坦治疗血管性痴呆患者临床疗效及对认知功能和生活质量的影响。方法将86例血管性痴呆患者按照随机数字表法分为两组,各43例。观察组给予银杏达莫注射液联合奥拉西坦注射液治疗,对照组给予常规治疗,观察2周。比较治疗前后两组简易智力状态检查量表、画钟试验及日常生活活动能力量表评分,比较两组临床疗效及不良反应发生率。结果治疗后两组简易智力状态检查量表及画钟试验评分均显著高于治疗前(P<0.01),观察组较对照组升高更显著(P<0.01)。治疗后两组Et常生活活动能力量表总分及各因子分均显著低于治疗前(P<0.01),观察组较对照组下降更显著(P<0.01)。观察组总有效率显著高于对照组(P<0.05),不良反应发生率显著低于对照组(P<0.05)。结论银杏达莫注射液联合奥拉西坦注射液治疗血管性痴呆患者疗效显著,能有效改善患者认知功能,提高生活质量,值得临床推广。
Objective To investigate the effects of ginkgo dipyridamole injection combined with oxiracetam injection on cognitive function and quality of life in patients with vascular dementia (VD).Methods 86 patients with VD were randomly divided into two groups,43 cases in each group.The observation group was treated with ginkgo dipyridamole injection combined with oxiracetam injection,and the control group was treated with conventional therapy for two weeks.The scores of MMSE,CDT and ALD were compared between the two groups before and after treatment,and the clinical efficacy and incidence of adverse reactions were compared between the two groups.Results After treatment,the scores of MMSE,CDT were significantly higher than those before treatment (P<0.01),and the observation group was increased more significantly than the control group (P<0.01).After treatment,the total scores of ALD and the scores of each factors were significantly lower than those before treatment (P<0.01),and the observation group was decreased more significantly than the control group (P<0.01).The total effective rate of the observation group was significantly higher than that of the control group (P<0.05),and the incidence of adverse reactions was significantly lower than that of the control group (P<0.05).Conclusion Ginkgo dipyridamole injection combined with oxiracetam injection in the treatment of VD can effectively improve the cognitive function,quality of life of patients,which is worthy of clinical promotion.
作者
戚颖
李萍
高文学
Qi Ying;Li Ping;Gao Wenxue(Kai feng City People's Hospital,Kai feng 475000,Henan,China)
出处
《临床心身疾病杂志》
CAS
2019年第1期100-102,共3页
Journal of Clinical Psychosomatic Diseases
